Navigating Patient Access Challenges In Commercializing Your CGT Product

Cell and gene therapies (CGTs) represent a transformative shift in personalized medicine, offering potential cures for conditions with limited treatment options. However, ensuring patient access remains a significant challenge for manufacturers due to financial burdens, logistical hurdles, and stakeholder coordination complexities. Addressing these barriers requires a multi-faceted approach, including improving awareness of patient support services, streamlining coordination across the treatment journey, and addressing geographic limitations that hinder access to specialized care.

Enhancing provider education on available financial and logistical support can help bridge gaps in patient enrollment and treatment adherence. Effective stakeholder collaboration — integrating manufacturers, healthcare providers, and patient advocacy groups — ensures a seamless transition from diagnosis to treatment. Additionally, expanding care site options and refining patient assistance programs can alleviate travel and financial burdens. By adopting these strategies, the industry can enhance accessibility and maximize the life-changing potential of CGTs for patients in need.